Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma
Status:
Recruiting
Trial end date:
2032-05-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study to find the ideal dose for the combination treatment of
Zanubrutinib and Tafasitamab in patients with mantle cell lymphoma. Another purpose is to
assess how well the combination treatment works in patients with the study disease.